The 19 most recent market catalysts affecting $HIMS, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Sep 15, 2026
Corporate Catalyst
Neutral
Impact 55
Watching Hims & Hers Health; Hearing Zacks Healthcare Innovators Newsletter Mentions Stock As A Buy
The mention of Hims & Hers Health as a 'Buy' in the Zacks Healthcare Innovators Newsletter is a positive, albeit short-term, catalyst. Such recommendations from well-known financia…
Sep 2, 2026
Corporate Catalyst
Bearish
Impact 65
Fraudulent Weight Loss Drugs: FDA Warns Against Mislabeled GLP-1 Medications
The FDA's warning against unapproved and compounded GLP-1 weight-loss medications directly impacts companies involved in their distribution, such as Hims & Hers Health Inc. (HIMS),…
Sep 1, 2026
Market Technicals
Neutral
Impact 55
How Did BONER Meme Coin Create One of Robinhood's Biggest Stories?
A meme coin, BONER, on Robinhood Chain created a liquidity squeeze for tokenized HIMS shares by absorbing over half of the available supply into its liquidity pool. This caused the…
Aug 21, 2026
Corporate Catalyst
Bearish
Impact 55
Barclays Maintains Overweight on Hims & Hers Health, Lowers Price Target to $35
Barclays analyst Glen Santangelo maintained an 'Overweight' rating on Hims & Hers Health, signaling continued confidence in the company's long-term prospects. However, the price ta…
Aug 11, 2026
Corporate Catalyst
Bullish
Impact 55
Deutsche Bank Maintains Hold on Hims & Hers Health, Raises Price Target to $26
Deutsche Bank analyst George Hill maintained a 'Hold' rating on Hims & Hers Health (HIMS) while raising the price target from $25 to $26. This action signals that the analyst sees …
Aug 11, 2026
Corporate Catalyst
Bearish
Impact 75
Hims & Hers Health shares are trading lower after the company reported mixed Q2 financial results.
The headline indicates a direct corporate catalyst impacting Hims & Hers Health. Mixed financial results, even with some positives, often lead to negative investor sentiment as exp…
Aug 11, 2026
Corporate Catalyst
Bullish
Impact 65
Needham Maintains Buy on Hims & Hers Health, Raises Price Target to $42
Needham analyst Ryan MacDonald maintained a 'Buy' rating on Hims & Hers Health and raised the price target from $35 to $42. This action indicates a strengthened positive outlook fr…
Aug 10, 2026
Corporate Catalyst
Bearish
Impact 92
Hims & Hers Shares Drop After Mixed Q2 Earnings — Details
Hims & Hers Health Inc. (HIMS) released its Q2 2026 earnings, showing a substantial miss on EPS (-$0.37 vs. -$0.03 consensus) but a beat on revenue ($753.21M vs. $699.889M). The co…
Aug 10, 2026
Corporate Catalyst
Bearish
Impact 92
Hims & Hers Health Q2 EPS $(0.37) Misses $(0.03) Estimate, Sales $753.214M Beat $699.889M Estimate
Hims & Hers Health (HIMS) released its Q2 earnings, revealing a mixed bag for investors. While the company significantly beat revenue estimates and demonstrated strong year-over-ye…
Aug 10, 2026
Corporate Catalyst
Bearish
Impact 75
Hims & Hers Stock Missed Estimates Last Quarter — Can It Turn the Page Tonight?
This filing provides a detailed preview of Hims & Hers Health Inc.'s upcoming Q2 earnings report, emphasizing that the company missed both EPS and revenue estimates in the previous…
Aug 10, 2026
Corporate Catalyst
Bullish
Impact 75
Hims & Hers Health Likely To Report Q2 Loss; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call
Hims & Hers Health is facing an anticipated Q2 loss, a notable shift from the previous year's profitability, which could negatively impact investor sentiment. However, the projecte…
Aug 6, 2026
Corporate Catalyst
Neutral
Impact 65
Hims & Hers Launches Intelligent AI Care Experience, Debuting With Hers Weight Loss Members To Deliver Personalized Guidance And Real-Time Progress Monitoring
Hims & Hers announced the launch of an intelligent AI care experience, initially for its Hers weight loss members. This development is significant as it integrates artificial intel…
Jul 31, 2026
Corporate Catalyst
Bullish
Impact 65
Hims & Hers Shares Rebound Friday: What's Driving the Move?
Hims & Hers Health is experiencing a rebound in its stock price, driven by technical support around its 100-day SMA, despite significant negative news. The company is facing a pote…
Jul 29, 2026
Corporate Catalyst
Bearish
Impact 85
Hims & Hers May Face FTC Lawsuit for Allegedly Sharing Sensitive User Data With Advertisers: Report
Hims & Hers Health Inc. (HIMS) is reportedly facing a major lawsuit from the FTC over allegations of unlawfully sharing sensitive customer health information with digital advertise…
Jul 29, 2026
Corporate Catalyst
Neutral
Impact 85
Hims & Hers On FTC Lawsuit, Says Lawsuit Disregards Substantial Evidence We Provided The FTC During Its Nearly Three-Year Investigation; We Are Confident In Our Position And Will Vigorously Defend Ourselves Against These Baseless Claims
Hims & Hers has disclosed that it is facing a lawsuit from the Federal Trade Commission (FTC). The company's statement indicates a strong disagreement with the FTC's claims, assert…
Jul 29, 2026
Corporate Catalyst
Bearish
Impact 95
Hims & Hers Health shares are trading lower after reports suggesting that the FTC is suing the company for selling its customer health data to Meta and Snap.
The reported FTC lawsuit against Hims & Hers Health for selling customer health data is a severe corporate catalyst. This directly impacts HIMS due to potential fines, legal costs,…
Jul 29, 2026
Corporate Catalyst
Neutral
Impact 85
'US FTC suing Hims & Hers for sending user health info to Meta, Snap' - Reuters Exclusive
The Reuters exclusive, referenced in the filing, reports that the FTC is suing Hims & Hers for allegedly transmitting sensitive user health data to Meta and Snap. This is a signifi…
Jul 23, 2026
Corporate Catalyst
Neutral
Impact 65
QUICK SPARK: Martin Shkreli Shorts Hims & Hers Stock, Says 'Peptides Are Fake Medicine'
Martin Shkreli, known for his controversial past in the pharmaceutical industry, publicly declared he is shorting Hims & Hers Health (HIMS) stock, labeling their peptide products a…
Jul 23, 2026
Corporate Catalyst
Bullish
Impact 85
Hims & Hers Health shares are trading higher after an FDA advisory panel voted to place BPC-157 peptide on an allowed pharmacy compounding list.
This FDA advisory panel vote is a significant positive catalyst for Hims & Hers Health, as it potentially expands their product offerings into the lucrative compounded medication m…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.